16. Ruzyllo W, Tendera M, Ford I. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67:393–405.
17. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540–8.
18. Meeter K, Kelder JC, Tijssen JG. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992;(20 Suppl 3):S59–66.
19. Ulvenstam G, Diderholm E, Frithz G. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992;(20 Suppl 3):S67–73.
20. Guermonprez JL, Blin P, Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993;14(Suppl B):S30–4.
21. Chatterjee T, Fleisch M, Meier B. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999;2:213–17.
22. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269–75.
23. Chaitman BR, Pepine CJ, Parker JO. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309–16.
24. Stone PH, Gratsiansky NA, Blokhin A. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566–75.
25. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and Clopidogrel in randomized controlled trials. Am J Med 2006;119:624–38.
26. Serebruany VL, Steinhubl SR, Berger PB. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005;95:1218–22.
27. Barnett H, Burrill P, Iheanacho I. Don't use aspirin for primary prevention of cardiovascular disease. BMJ 2010;340:c1805.
28. Braunwald E, Domanski MJ, Fowler SE. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New Engl J Med 2004;351:2058–68.
29. Yusuf S, Sleight P, Pogue J. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med 2000;342:145–53.
30. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253–9.
31. Daly CA, De SB, Sendon JL. Predicting prognosis in stable anginadresults from the Euro heart survey of stable angina: prospective observational study. BMJ 2006;332:262–7.
32. Clayton TC, Lubsen J, Pocock SJ. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomized trial cohort of patients. BMJ 2005;331:869.
33. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501–55.
34. Berry J, Dyer A, Cai X. Lifetime risks of cardiovascular disease. N. Engl.J.Med. 2012; 366. 321-9
35. Hachamovitch R, Hayes SW, Friedman JD. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107:2900–7.
36. Shaw LJ, Berman DS, Maron DJ. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283–91.
37. Rogers WJ, Coggin J, Gersh B. Ten-year follow-up of quality of life in patients randomised to receive medical therapy or coronary artery bypass surgery. The coronary artery bypass surgery study. Circulation 1990;82:1647–58.
38. Henderson RA, Pocock SJ, Clayton TC. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003;42:1161–70.
39. European Society of Cardiology. EVINCI results could lead to 75 percent reduction of invasive procedures for patients with suspected CAD. June 26, 2012. Disponible en: lwww.escardio.org/evinci. Útimo acceso julio 2012.
40. Boden WE, O'Rourke RA, Teo KK. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503–16.
41. Yusuf S, Zucker D, Peduzzi P. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344:563–70.
42. Gyenes GT, Ghali WA. Should all patients with Asymptomatic but significant (>50%) left main coronary artery stenosis Undergo surgical revascularization? Circulation 2008;118:422–5.
43. Hartigan PM, Giacomini JC, Folland ED. Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Veterans Affairs Cooperative Studies Program ACME Investigators. Angioplasty Compared to Medicine. Am J Cardiol 1998;82:1445–50.
44. Pitt B, Waters D, Brown WV. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. New Engl J Med 1999;341:70–6.
45. Hueb WA, Soares PR, Almeida DO. Five-year follow-op of the medicine, angioplasty, or surgery study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. Circulation 1999;100:II107–13.
46. Hueb W, Lopes N, Gersh BJ. Ten-Year follow-up survival of the medicine, angioplasty, or surgery study (MASS II). Circulation 2010;122:949–57.
47. The BARI 2D study group. A randomized trial of Therapies for type 2 diabetes and coronary artery disease. New Engl J Med 2009;360:2503–15.
48. Hlatky MA, Boothroyd DB, Melsop KA. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes trial. Circulation 2009;120:2550–8.
49. Hlatky MA, Boothroyd DB, Bravata DM. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009;373:1190–7.
50. Kapur A, Hall RJ, Malik IS. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in Diabetic patients: 1-Year results of the CARDia (Coronary artery revascularization in diabetes) trial. J Am Coll Cardiol 2010;55:432–40.
51. Kappetein AP, Feldman TE, Mack MJ. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011;32:2125–34.
52. Stone GW, Rizvi A, Newman W. Everolimus-Eluting versus paclitaxel-eluting stents in coronary artery disease. New Engl J Med 2010;362:1663–74.
53. Kedhi E, Joeseof KS, McFadden E. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201–9.
54. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents: a hierarchical Bayesian meta-analysis. Ann Intern Med 2003;138:777–86.
55. Kirtane AJ, Gupta A, Iyengar S. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009;119:3198–206.
56. Stettler C, Wandel S, Alleman S. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937–48.
57. European Society of Cardiology. EVINCI results could lead to 75 percent reduction of invasive procedures for patients with suspected CAD. June 26, 2012. Disponible en: www.escardio.org/evinci. Último acceso julio 2012.
58. The Society for Cardiothoracic Surgery (London) and by Dendrite Clinical Systems (Henley-on-Thames). Sixth National Adult Cardiac Surgical DatabaseReport. 2008. Disponible en;
http://www.scts.org/_userfiles/resources/SixthNACSDreport2008withcovers.pdf. Último acceso julio 2012